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Background/aim: Cardiovascular complications, including ventricular arrhythmias associated with abnormalities of ventricular
repolarization, are the leading cause of morbidity and mortality in patients with acromegaly. Herein, we aimed to investigate ventricular
repolarization using Tp–e interval, Tp-e interval/QT, and Tp-e interval/QTc ratios in acromegalic patients compared to healthy subjects.
Materials and methods: A total of 29 patients (aged 51.9 ± 11.2, 65.5% women) with acromegaly and 30 control subjects (aged 47.3
± 14.4, 63.3% women) were enrolled in the study. Tp–e and QT interval, corrected QT (QTc), Tp–e/QT, and Tp–e/QTc ratios were
calculated from the 12-lead electrocardiogram.
Results: Tp-e interval (89.28 ± 12.16 vs. 75.97 ± 9.92 ms; p < 0.001), Tp-e/QT ratio (0.237 ± 0.045 vs. 0.212 ± 0.029; p = 0.019), and Tp-e/
QTc ratio (0.218 ± 0.031 vs. 0.195 ± 0.026; p = 0.003) were significantly higher in patients with acromegaly compared to control group.
A positive correlation was determined between left atrial volume index (LAVI) and Tp-e interval (r = 0.272, p = 0.039).
Conclusion: The current study is the first to have shown significantly increased Tp-e interval, Tp-e/QT ratio, and Tp-e/QTc ratio were
increased in acromegalic patients. These results may be important for screening malignant arrhythmic events in acromegaly.
Key words: Acromegaly, arrhythmogenesis, Tp-e interval

1. Introduction
Acromegaly is a rare disorder resulting from excessive growth
hormone production (GH) and serum insulin like growth
factor-1 (IGF-1) concentrations [1]. GH and IGF-1 excess
are strongly linked to the development of cardiovascular
complications including life-threatening arrhythmias,
cardiomyopathy, hypertension, atherosclerosis, or valvular
heart disease [2,3]. Cardiovascular complications are
the most common causes of morbidity and mortality
especially in patients with active acromegaly but frequently
develop after adequate treatment in patients with the
controlled disease [3–5]. The presence of cardiovascular
comorbidities significantly increases the risk of morbidity
and mortality in acromegalic patients than in the general
population [3,6]. Malignant ventricular arrhythmia may
develop in patients with acromegaly which is related to
sudden cardiac death [7].
Ventricular repolarization abnormalities are central
elements in arrhythmogenesis. Previous studies showed
that ventricular repolarization can be evaluated by QT
interval (QT), corrected QT interval (QTc), QT dispersion
(QTd), and T wave measurements [8,9]. The time between

the peak and the end of the T wave (Tp‐e interval) is a
measure of transmural dispersion of repolarization time
and seems to play a major role in arrhythmogenesis
[10,11]. Increased Tp-e interval, Tp-e interval/QT,
and Tp-e interval/QTc ratios have been accepted as
electrocardiographic markers to predict ventricular
arrhythmias and cardiovascular mortality [12,13].
However, the Tp-e/QT ratio has been emphasized among
the more accurate marker of ventricular repolarization
[13,14].
The aim of the present study was to assess ventricular
repolarization parameters of acromegalic patients using
Tp-e interval, Tp-e interval/QT, and Tp-e interval/QTc
ratios. To our knowledge, no prior studies have examined
previously the association between these parameters and
acromegaly.
2. Methods
2.1. Study population
In this study, we enrolled consecutively eligible outpatients
of the Endocrinology Department with the diagnosis
of acromegaly. A total of 33 acromegalic patients and 30
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healthy individuals were enrolled in the study, 4 acromegalic
patients were excluded. Patients with renal dysfunction (n
= 2), acute or chronic infection, cardiovascular diseases
including ischaemic heart disease (n = 1), congestive
heart failure, severe valvular heart disease, abnormal
serum electrolyte values (n = 1), pregnancy, malignancy,
left and right bundle branch block, Mobitz type II, thirddegree atrioventricular block, ventricular preexcitation,
atrial fibrillation, a permanent pace-maker, severe kidney,
liver and lung disease, those taking any class I and III
antiarrhythmic medication were excluded from the study.
Therefore, 29 patients with acromegaly and 30 gender and
age-matched healthy volunteers were included in the study
after exclusion criteria were applied.
2.2. Electrocardiography
The 12-lead electrocardiogram (ECG) was recorded at a
paper speed of 50 mm/s (Mortara, Milwaukee, USA) at
rest in the supine position. All of the ECGs were scanned
and then Adobe Photoshop software was used for ×400%
magnification. ECG measurements of QT and Tp-e
intervals were performed by two cardiologists who did
not know the patient data. The Tp-e interval was defined
as the difference between the peak of the T wave and the
end of the T wave. The U wave was excluded from the
Tp-e interval. The QT interval was measured from the
beginning of the QRS complex to the end of the T wave
and Corrected QT (QTc) was calculated with the Bazett
formula: cQT = QT√(R–R interval). Measurements of the
Tp-e interval were evaluated from precordial leads. The
Tp-e/QT ratio was calculated from these measurements.
Additionally, twenty-four hour holter recordings were
evaluated by using three-channel analog recorders using
the ELATEC Holter system.
2.3. Echocardiography
The echocardiographic assessment was analysed by using
a Vivid S60N Dimension Cardiovascular Ultrasound
System (Vingmed-General Electric, Horten, Norway) with
a 3.5 MHz transducer in the left lateral decubitus position.
Parasternal long and short-axis views and apical views were
used as standard imaging windows. The ejection fraction
was calculated by using the modified Simpson method.
Septal and posterior walls’ thickness, left ventricular
(LV) end-systolic and end-diastolic dimensions left atrial
diameter were measured from parasternal long-axis view.
Tissue Doppler imaging (TDI) was acquired from the
lateral and septal walls of the left ventricular basal section.
E/A ratio and E/e’ ratios were analysed in the evaluation of
LV diastolic function. Left ventricular mass index (LVMI)
was calculated by the ratio of calculated LV mass to the
body surface. Left ventricular hypertrophy (LVH) was
defined as the calculation of LVMI > 115 g/m2 in men
and >95 g/m2 in women. Left atrial (LA) volume was
assessed by the biplane area-length method from apical
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4- and 2-chamber views. LA volume/body surface area
was measured for LA volume index (LAVI). All these
echocardiographic measurements were performed by
experienced investigators according to standards outlined
by the American Society of Echocardiography guidelines
[15].
2.4. Laboratory evaluation
Serum GH and IGF-1 levels were measured by using
cobas 8000 Modular Analyzer Series (Roche Diagnostics,
Mannheim, Germany). Biochemical measurements
including fasting blood glucose, total cholesterol, lowdensity lipoprotein (LDL) cholesterol, high-density
lipoprotein (HDL) cholesterol, triglyceride, serum
creatinine, serum electrolytes were evaluated using cobas
8000 Modular Analyzer Series (Roche Diagnostics,
Mannheim, Germany) (Abbott Aeroset, USA). Complete
blood count (CBC) was calculated by an automated
analyzer (Sysmex SF-3000 Hematology Analyzer, USA).
2.5. Statistical analysis
All data analyses were performed with SPSS version 22.0
(SPSS, Inc, Chicago, Illinois). Categorical variables are
expressed as counts and percentages, and continuous
variables are presented as mean ± standard deviation or
as median and interquartile ranges. Categorical variables
were compared by the chi-square test or Fisher’s exact tests
as appropriate. Comparisons of parametric values between
the 2 groups were compared using independent samples
t-test. Comparisons of nonparametric values between
the 2 groups were done by Mann-Whitney U test. The
goodness of fit of the model was evaluated by the HosmerLemeshow test. Pearson correlation analysis was performed
to examine the relationship between Tp–e interval, Tp–e/
QT ratio, and Tp–e/QTc and other variations. A 2-sided
p-value of < 0.05 was considered statistically significant.
3. Results
The baseline clinical characteristics and laboratory
parameters of the patients are shown in Table 1. The mean
age of the subjects was 51.9 ± 11.2 years, and 19 (65.5%)
of the patients were female. There was no statistically
significant difference between the groups in terms of age,
gender, hypertension, diabetes mellitus, hyperlipidemia,
smoking habitus, and basal laboratory findings (p >
0.05). However, body mass index (BMI) was higher in the
acromegaly group (p < 0.001). Also, serum GH (1.39 (3.37–
0.55) vs. 0.32 (0.78–0.09); p < 0.001) and IGF-1 (249.9 ±
189.3 ng/mL vs. 147.1 ± 39.6 ng/m; p = 0.009) levels were
significantly higher in patients with acromegaly.
The electrocardiographic and echocardiographic
findings are given in Table 2. The mean heart rate (78.4
± 9.8 vs. 76.9 ± 14.4 per minute; p = 0.638) was similar
between the groups. QRS duration (94.3 ± 13.1 vs. 86.2 ±
8.3; p = 0.007), QT (380.2 ± 28.8 vs. 357.5 ± 17.3 ms; p =
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Table 1. Baseline characteristics and laboratory parameters of the study subjects.
Control group
(n = 30)

Acromegaly
(n = 29)

p value

Age (years)

47.3 ± 14.4

51.9 ± 11.2

0.183

Women, n (%)

19 (63.3%)

19 (65.5%)

0.861

Body mass index (kg/m2)

25.5 ± 4.5

30.5 ± 5.7

<0.001

Hypertension, n (%)

5 (16.6%)

11 (37.9%)

0.066

Diabetes mellitus, n (%)

10 (33.3%)

12 (41.3%)

0.523

Current smoker, n (%)

9 (30.0%)

10 (31.0%)

0.931

Hypercholesterolemia, n (%)

4 (13.3%)

11 (37.9%)

0.066

Hemoglobin (g/dL)

13.8 ± 1.5

13.1 ± 1.2

0.079

Serum creatinine (mg/dL)

0.71 ± 0.14

0,73 ± 0.17

0.712

Sodium (mEq/L)

14.1 ± 3.2

140.6 ± 3.1

0.556

Potassium (mmol/L)

4.4 ± 0.2

4.4 ± 0.2

0.979

Calcium (mg/dL)

9.5 ± 0.4

9.6 ± 0.7

0.428

Magnesium (mmol/L)

0.81 ± 0.06

0.78 ± 0.08

0.117

Total cholesterol (mg/dL)

175.0 ± 31.1

171.6 ± 43.1

0.756

High density lipoprotein cholesterol (mg/dL)

51.9 ± 14.7

48.9 ± 12.1

0.431

Low density lipoprotein cholesterol (mg/dL)

99.6 ± 26.2

90.9 ± 38.5

0.357

Triglyceride (mg/dL)

99 (158–70)

111.0 (211.2–83.0)

0.092

GH (ng/mL)

0.32 (0.78–0.09)

1.39 (3.37–0.55)

<0.001

GF-1 (ng/mL)

147.1 ± 39.6

249.9 ± 189.3

0.009

Data are given as mean ± standard deviation, median (interquantile range) or n (%). GH growth hormone, IGF
insulin-like growth factor.

0.001), and QTc intervals (409.6 ± 15.1 vs. 389.5 ± 14.0; p
< 0.001) were determined to be statistically significantly
higher in the acromegaly group. Additionally, Tp-e interval
(89.28 ± 12.16 vs. 75.97 ± 9.92 ms; p < 0.001), Tp-e/QT
(0.237 ± 0.045 vs. 0.212 ± 0.029; p = 0.019), and Tp-e/QTc
ratios (0.218 ± 0.031 vs. 0.195 ± 0.026; p = 0.003) were
also significantly increased in patients with acromegaly
compared to control group (Figure 1). We had 24 h holter
recordings of study groups and 3 of 29 acromegalic patients
had non sustained ventricular tachyarrhythmias (NSVT).
Acromegaly patient with NSVT attack had similar QRS
duration (112 ± 10.1 vs. 90.1 ± 10.3; p = 0.062), QT (402
± 25.2 vs. 366.9 ± 24.9 ms; p = 0.067), and QTc intervals
(405,4 ± 15.6 vs. 397.7 ± 16; p = 0.075), Tp-e interval (82 ±
8.7 vs. 80.5 ± 10.1 ms; p = 0.660), Tp-e/QT (0.203 ± 0.011
vs. 0.220 ± 0.028; p = 0.147), and Tp-e/QTc ratios (0.192 ±
0.019 vs. 0.202 ± 0.026; p = 0.523) with acromegaly patient
without NSVT attack.
There were no significant differences between the two
groups in the echocardiographic dimensions including the
left ventricular ejection fraction, left ventricle end-diastolic
diameter and left ventricle end-sistolic diameter (p >
0.05). Acromegalic patients exhibited significantly higher

values in interventricular septum (9.9 ± 1.5 vs. 8.8 ± 1.4;
p = 0.005), left ventricular posterior wall thickness (9.5
± 1.3 vs. 8.7 ± 1.4; p = 0.032) , LVMI (90.8 ± 24.9 vs. 74.6
± 15.0; p = 0.004) and left atrial diameter (36.4 ± 4.3 vs.
29.8 ± 4.6; p < 0.001) compared to control group. Similarly,
LA volume (45.9 ± 17.0 vs. 34.1 ± 9.4; p = 0.002), LA area
(16.9 ± 3.9 vs. 13.2 ± 2.5; p < 0.001) and LAVI (23.3 ± 7.7
vs. 18.6 ± 3.8; p = 0.006) were also significantly higher
in patients with acromegaly. TDI demonstrated e’ lateral
value (11.1 ± 2.7 vs. 13.5 ± 2.9; p = 0.02) was significantly
lower in acromegalic patients. Additionally, no significant
difference was observed between E/A and E/e’ values of
patients between the groups (p > 0.05).
Finally, the Pearson correlation coefficient was
performed to estimate the correlation between LAVI and
Tp-e interval. We found a significant positive correlation
between LAVI and Tp-e interval (r = 0.272, p = 0.039;
Figure 2).
4. Discussion
In this study, we evaluated ventricular repolarization
parameters in patients with acromegaly and compared
them with healthy control subjects. Our study results
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Table 2. Electrocardiographic and echocardiographic findings of the study population.
Control group
(n = 30)

Acromegaly
(n = 29)

p value

Heart rate (bpm)

78.4 ± 9.8

76.9 ± 14.4

0.638

Tp–e interval (ms)

75.97 ± 9.92

89.28 ± 12.16

<0.001

QT interval (ms)

357.5 ± 17.3

380.2 ± 28.8

0.001

QTc interval (ms)

389.5 ± 14.0

409.6 ± 15.1

<0.001

QRS interval (ms)

86.2 ± 8.3

94.3 ± 13.1

0.007

Tp-e/QT ratio

0.212 ± 0.029

0.237 ± 0.045

0.019

Tp–e/QTc ratio

0.195 ± 0.026

0.218 ± 0.031

0.003

LVEF (%)

63.6 ± 4.9

62.4 ± 5.4

0.414

LVEDD (mm)

46.4 ± 5.2

48.8 ± 4.5

0.067

LVESD (mm)

30.3 ± 4.3

31.7 ± 4.0

0.206

IVS (mm)

8.8 ± 1.4

9.9 ± 1.5

0.005

PW (mm)

8.7 ± 1.4

9.5 ± 1.3

0.032

LVMI (g/m2)

74.6 ± 15.0

90.8 ± 24.9

0.004

Left atrial diameter (mm)

29.8 ± 4.6

36.4 ± 4.3

<0.001

LAa (cm2)

13.2 ± 2.5

16.9 ± 3.9

<0.001

LAv (cm3)

34.1 ± 9.4

45.9 ± 17.0

0.002

LAVI (mL/m2)

18.6 ± 3.8

23.3 ± 7.7

0.006

E/A ratio

1.2 ± 0.3

1.0 ± 0.3

0.051

e’ lateral (cm/s)

13.5 ± 2.9

11.1 ± 2.7

0.003

E/e’ ratio

5.5 ± 1.2

6.4 ± 2.4

0.116

Data are represented as mean values ± SD or (%). LVEF Left ventricular ejection fraction, LVEDD
Left ventricle end-diastolic diameter, LVESD Left ventricle end-systolic diameter, LAa Left
atrial area, LAv Left atrial volume, LAVI left atrial volume index, IVS Interventricular septum
thickness, PW Posterior wall diameter, LVMI Left ventricular mass index mm millimeters, bpm
beats per minute, ms milliseconds.

Figure 1. Comparison of Tp-e Interval, Tp-e/QT, and Tp-e/QTc ratios between acromegalic patients and healthy control subjects.

indicate that acromegalic patients had longer Tp-e interval,
Tp-e/QT, and Tp-e/QTc ratios when compared to healthy
subjects. To the best of our knowledge, this study was the
first clinical trial focusing on the Tp–e interval, Tp–e/QT,
Tp–e/QTc ratios in acromegalic patients.
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Cardiovascular diseases are one of the most prevalent
in acromegalic patients and in 60% of uncontrolled
acromegalic patients die from cardiovascular comorbidities
[16,17]. In this regard, hypertension, cardiomyopathy, heart
valve disease, atherosclerosis, and coronary artery disease
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Figure 2. Correlation between Tp-e interval and left atrium
volume index (LAVI).

are important manifestations of cardiac involvement
in patients with acromegaly [3,18]. Cardiac rhythm
abnormalities are also frequent and ectopic beats, bundle
branch block, paroxysmal atrial fibrillation, paroxysmal
supraventricular tachycardia, sick sinus syndrome, and
ventricular tachycardia have been demonstrated [18,19].
The underlying pathophysiological mechanisms of each
cardiac involvement may not be fully understood but
persistent GH and IGF-I excess, age, prolonged disease
duration, and coexistence of other cardiovascular risk
factors may play an important role as predisposing
factors [18]. GH and IGF-1 excess are strongly related
to the development of cardiovascular complications,
especially in patients with active acromegaly but
frequently persist after adequate treatment in patients
with the controlled disease [3,4]. GH and IGF-1 have
various negative effects on the cardiovascular system
like microvascular inflammation, oxidative stress,
and endothelial dysfunction which may explain the
development of cardiovascular complications [4].
Ventricular repolarization parameters are related to
malignant arrhythmias and have prognostic significance
in terms of mortality and sudden cardiac death. Several
studies have shown that QT, QTc, QTd, and T wave
measurements were clarified as a sign of increased
dispersion of ventricular repolarization [8,9]. Tp‐e
interval which is a measure of transmural dispersion
of repolarization time seems to play a major role in
arrhythmogenesis [10,11]. Increased Tp-e interval, Tp-e
interval/QT, and Tp-e interval/QTc ratios have been
evaluated as electrocardiographic markers of ventricular
arrhythmias and cardiovascular mortality [12,13]. Due

to the interaction with the QT and heart rate and body
weight, Tp-e/QTc ratio has been emphasized as a better
indicator of ventricular repolarization [10,13]. Prolonged
Tp-e interval was associated with increased mortality in
QT syndrome and Brugada syndrome [12,13]. In recent
years, Tp-e interval, Tp-e interval/QT, and Tp-e interval/
QTc ratios have been investigated in many diseases.
Yenercağ et al. [20] demonstrated that Tp-e interval, Tp-e/
QT, and Tp-e/QTc ratios were significantly increased in
Fabry patients. Another study showed that Tpe, Tpe/QT,
and Tpe/QTc ratios were higher in acute myocarditis
patients [21]. Moreover, Tp-e interval, Tp-e/QT ratio,
and Tp-e/QTc ratio were increased in asymptomatic
arrhythmogenic right ventricular cardiomyopathy
patients [22].
Malignant ventricular arrhythmias and sudden death
can be seen higher in acromegalic patients compared to
the general population [23]. The severity of ventricular
arrhythmias was associated with the duration of disease
and correlated with left ventricular mass [19]. The
main factor involved in the onset and progression of
arrhythmia in acromegaly is thought to be myocardial
interstitial fibrous due to GH and IGF-1 excess [24].
The determination of clinical predictors of ventricular
arrhythmias is important in acromegalic patients.
Previous studies have evaluated QT intervals in patients
with acromegaly to identify patients at high risk for
sudden death and prolonged QT duration was observed
in acromegaly [23,25]. Dural et al. [26] also investigated
cardiac autonomic dysfunction for early identification
of acromegalic patients at higher risk. Additionally, the
occurrence of late potentials, which is an indicator of the
risk of ventricular arrhythmia, was higher in patients with
acromegaly [27]. Consistent with previous reports, in our
study, we observed prolonged QT intervals. However,
noninvasive and easy measurable ECG parameters, such
as Tp-e interval, Tpe/QT, and Tpe/QTc ratios have not
been investigated in patients with acromegaly before. In
the current study, Tp-e interval, Tp-e/QT, and Tp-e/QTc
ratios were significantly higher in acromegalic patients
than in control subjects.
The relationship between diastolic dysfunction
and Tp-e interval, Tp-e/QT, and Tp-e/QTc ratios
which may be related to cardiomyocyte involvement
and increased risk of arrhythmia has been shown in
Fabry patients [20]. Regarding the evaluation of left
ventricular diastolic dysfunction in acromegaly, Cansu
et al. [28] investigated diastolic dysfunction parameters
in acromegalic patients compared to normal individuals
and found that LAVI, a diagnostic criterion for diastolic
dysfunction, was significantly higher in the patients
with acromegaly. In addition, it was reported that LAVI
was a potential predictor of arrhythmias and adverse
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outcomes in patients with hypertrophic cardiomyopathy
including sudden cardiac death [29]. In this regard, we
analyzed the relationship between diastolic dysfunction
and ventricular arrhythmia parameters in our study. A
significant positive correlation was detected between
the LAVI and Tp-e interval in the study cohort. Thus,
diastolic dysfunction in acromegalic patients may be
associated with a higher risk of arrhythmia.
The results of the current study should be assessed
with some limitations. First, this study is a single-center
and relatively small sample population. Second, this
is a cross-sectional study so we could not follow the
arrhythmic episodes of patients. Finally, we did not have
the data demonstrating at what time point when the
Tp-e interval, Tp-e/QT, and Tp-e/QTc ratios started to
prolong or change following diagnosis of acromegaly.
Future large, prospective and randomized clinical trials
are required to assess the clinical applicability of our
findings.

5. Conclusion
In conclusion, Tp-e interval, Tp-e/QT, and Tp-e/QTc
ratios were increased in patients with acromegaly, which
may indicate a higher risk for ventricular arrhythmias
in patients with acromegaly. Tp-e interval, Tp-e/QT, and
Tp-e/QTc ratios are simple, inexpensive, and noninvasive
methods that may be valuable for screening for ventricular
repolarization in acromegalic patients.
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